LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC

• المؤلفون الرئيسيون: Xinyin Liu (مؤلف), Xiyi Lu (مؤلف), Fuxi Zhen (مؤلف), Shidai Jin (مؤلف), Tongfu Yu (مؤلف), Quan Zhu (مؤلف), Wei Wang (مؤلف), Kun Xu (مؤلف), Jiaqi Yao (مؤلف), Renhua Guo (مؤلف)
• التنسيق: كتاب
• منشور في: Elsevier, 2019-06-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor, has been used as the first choice of treatment for advanced non-small-cell lung cancer. However, during the course of treatment, cancer cells often develop resistance to gefitinib without fully understood mechanisms. In this...